Product Name:7-benzyl-2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine

IUPAC Name:7-benzyl-2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine

CAS:1059735-34-0
Molecular Formula:C14H13Cl2N3
Purity:97%
Catalog Number:CM105615
Molecular Weight:294.18

Packing Unit Available Stock Price($) Quantity
CM105615-25g in stock ǕƱŴ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:1059735-34-0
Molecular Formula:C14H13Cl2N3
Melting Point:-
Smiles Code:ClC1=C2C(CN(CC3=CC=CC=C3)CC2)=NC(Cl)=N1
Density:
Catalog Number:CM105615
Molecular Weight:294.18
Boiling Point:
MDL No:MFCD11846183
Storage:Cool,ventilated,dry

Category Infos

Column Infos

Adagrasib
Jan. 10, 2024, EC approves KRAZATI (adagrasib) as a targeted treatment option for patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation.
Adagrasib is an orally available, potent, irreversible, small molecule inhibitor of KRAS G12C mutant isoform for the treatment of solid tumours harbouring KRAS G12C oncogenic driver mutation. Adagrasib covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in its inactive state, thereby preventing downstream signalling without affecting wild-type KRAS protein.

Related Products